Pharma is built to overcome, but focus on fundamentals remains key.
A recent analysis of the biotech market shows promising signs.
The recent flurry of Q1 earnings reports offer a unique opportunity to assess the real-time impacts of COVID-19 on the sector.
Considerations for biopharma to transform itself beyond the COVID-19 crisis, by Arda Ural.